Discovery of highly potent and selective small molecule ADAMTS-5 inhibitors that inhibit human cartilage degradation via encoded library technology (ELT).

The metalloprotease ADAMTS-5 is considered a potential target for the treatment of osteoarthritis. To identify selective inhibitors of ADAMTS-5, we employed encoded library technology (ELT), which enables affinity selection of small molecule binders from complex mixtures by DNA tagging. Selection of ADAMTS-5 against a four-billion member ELT library led to a novel inhibitor scaffold not containing a classical zinc-binding functionality. One exemplar, (R)-N-((1-(4-(but-3-en-1-ylamino)-6-(((2-(thiophen-2-yl)thiazol-4-yl)methyl)amino)-1,3,5-triazin-2-yl)pyrrolidin-2-yl)methyl)-4-propylbenzenesulfonamide (8), inhibited ADAMTS-5 with IC(50) = 30 nM, showing >50-fold selectivity against ADAMTS-4 and >1000-fold selectivity against ADAMTS-1, ADAMTS-13, MMP-13, and TACE. Extensive SAR studies showed that potency and physicochemical properties of the scaffold could be further improved. Furthermore, in a human osteoarthritis cartilage explant study, compounds 8 and 15f inhibited aggrecanase-mediated (374)ARGS neoepitope release from aggrecan and glycosaminoglycan in response to IL-1β/OSM stimulation. This study provides the first small molecule evidence for the critical role of ADAMTS-5 in human cartilage degradation.

[1]  David R. Liu,et al.  Small-molecule discovery from DNA-encoded chemical libraries. , 2011, Chemical Society reviews.

[2]  R. Copeland,et al.  Aggrecan Protects Cartilage Collagen from Proteolytic Cleavage* , 2003, Journal of Biological Chemistry.

[3]  Masahiro Tanaka,et al.  Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors. , 2011, Journal of medicinal chemistry.

[4]  H. Ma,et al.  Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice. , 2004, Arthritis and rheumatism.

[5]  H. Ma,et al.  Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis , 2005, Nature.

[6]  M. Tortorella,et al.  Inhibition of ADAM-TS4 and ADAM-TS5 Prevents Aggrecan Degradation in Osteoarthritic Cartilage* , 2002, The Journal of Biological Chemistry.

[7]  Advances in the development of novel aggrecanase inhibitors , 2011, Expert opinion on therapeutic patents.

[8]  R W Farndale,et al.  A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. , 1982, Connective tissue research.

[9]  F. de Rienzo,et al.  Progress towards the identification of new aggrecanase inhibitors. , 2009, Current medicinal chemistry.

[10]  S. Kumar,et al.  Development and characterization of a highly specific and sensitive sandwich ELISA for detection of aggrecanase-generated aggrecan fragments. , 2006, Osteoarthritis and cartilage.

[11]  K. Huang,et al.  Aggrecanase and Aggrecan Degradation in Osteoarthritis: A Review , 2008, The Journal of international medical research.

[12]  Dario Neri,et al.  20 years of DNA-encoded chemical libraries. , 2011, Chemical communications.

[13]  R. Black,et al.  Identification and Characterization of 4-[[4-(2-Butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a Novel Dual Tumor Necrosis Factor-α-Converting Enzyme/Matrix Metalloprotease Inhibitor for the Treatment of Rheumatoid Arthritis , 2004, Journal of Pharmacology and Experimental Therapeutics.

[14]  M. Tortorella,et al.  Will the real aggrecanase(s) step up: evaluating the criteria that define aggrecanase activity in osteoarthritis. , 2008, Current pharmaceutical biotechnology.

[15]  D. Griggs,et al.  Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. , 2007, Arthritis and rheumatism.

[16]  R. Wynn,et al.  Cloning and Characterization of ADAMTS11, an Aggrecanase from the ADAMTS Family* , 1999, The Journal of Biological Chemistry.

[17]  R. Matico,et al.  TIMP-3 Inhibition of ADAMTS-4 (Aggrecanase-1) Is Modulated by Interactions between Aggrecan and the C-terminal Domain of ADAMTS-4* , 2007, Journal of Biological Chemistry.

[18]  C. Flannery.  Novel therapies in OA. , 2010, Current drug targets.

[19]  Baoguang Zhao,et al.  Design, synthesis and selection of DNA-encoded small-molecule libraries. , 2009, Nature chemical biology.

[20]  I. Otterness,et al.  Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13. , 2005, Bioorganic & medicinal chemistry letters.

[21]  R. Wynn,et al.  Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. , 1999, Science.

[22]  A. Fourie,et al.  ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro , 2005, Nature.

[23]  L. Mosyak,et al.  Crystal structures of the two major aggrecan degrading enzymes, ADAMTS4 and ADAMTS5 , 2008, Protein science : a publication of the Protein Society.

[24]  L. Lohmander,et al.  Synovial fluid level of aggrecan ARGS fragments is a more sensitive marker of joint disease than glycosaminoglycan or aggrecan levels: a cross-sectional study , 2009, Arthritis Research & Therapy.

[25]  M. Clark,et al.  Selecting chemicals: the emerging utility of DNA-encoded libraries. , 2010, Current opinion in chemical biology.